Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAT | P04040 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23843890 | 1.00 | CAT (0.63) | CATL3MBTL1 | |
| SCHEMBL23843891 | 1.00 | CAT (0.63) | CATL3MBTL1 | |
| SCHEMBL25471561 | 1.00 | CAT (0.63) | CATL3MBTL1 | |
| SCHEMBL21012422 | 0.89 | CAT (0.65) | CATL3MBTL1 | |
| SCHEMBL23655031 | 0.89 | CAT (0.65) | CATL3MBTL1 | |
| SCHEMBL21012495 | 0.89 | CAT (0.59) | CAT | |
| SCHEMBL23655018 | 0.89 | CAT (0.59) | CAT | |
| SCHEMBL23654995 | 0.86 | CAT (0.61) | CAT | |
| SCHEMBL23655053 | 0.86 | CAT (0.61) | CAT | |
| SCHEMBL23655316 | 0.86 | CAT (0.61) | CAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151029-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | QPEX BIOPHARMA, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230151029-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | QPEX BIOPHARMA, INC. | 2023-05-18 | — | — | US | disclosed |
| WO-2023278945-A1 | CRYSTALLINE FORMS OF CEFTIBUTEN | QPEX BIOPHARMA, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2021188700-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | QPEX BIOPHARMA, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151029-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | BLVRB, BLK, BTD | CAT 268/4885L3MBTL1 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.